12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Interim postmarketing study data

Interim data from the international TYNERGY trial in 195 patients showed that Tysabri significantly reduced median FSMC scores by 9 points from baseline to 12 months (p<0.0001). Tysabri also led to significant reductions in the motor and cognitive components of the FSMC score (p<0.0001 for both),...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >